Wire · opportunities
New Blood Test for Alzheimer's Gets FDA Clearance—Here's How It Works
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 4 September 2026 · Fusion42 review
The FDA has approved PrecivityAD2, a new blood test by C2N Diagnostics for adults aged 40 and older undergoing Alzheimer's assessment. The test detects brain amyloid plaques to support clinical evaluation and is not intended as a standalone screening tool.
This Wire brief sits within Fusion42's coverage of Medtech, and 11 sources have reported it between 20 Aug 2026 and 4 Sep 2026.
◆ ◆ The Wire takeaway
Medtech founders know the door just opened for blood-based Alzheimer's diagnostics in the US. You need to move fast to integrate or compete with C2N Diagnostics' new test now approved for aiding diagnosis in symptomatic adults.
◆ Coverage
11 sources · first reported 20 Aug 2026 · latest 4 Sep 2026
◆ Related on Wire
◆ Topics